News Room
TechnoPhage S.A. announces spin-off of T-Oncology AG
TechnoPhage announced the spin-off of T-Oncology AG, which will focus on the development of Antibody Drug Conjugates (ADCs), based on the...
Technophage has been listed as ‘One of FT1000’s Fastest-Growing Companies in Europe’
The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times'...
Technophage granted with the ‘COTEC Innovative Status 2022′
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2022’. COTEC Portugal is the main Portuguese...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology